Geode Capital Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-414,344
| Closed | -$289K | – | 4823 |
|
|
2023
Q1 | $289K | Buy |
414,344
+5,236
| +1% | +$4.82K | ﹤0.01% | 3877 |
|
|
2022
Q4 | $368K | Buy |
409,108
+217,663
| +114% | +$631K | ﹤0.01% | 3817 |
|
|
2022
Q3 | $1.15M | Buy |
191,445
+26,707
| +16% | +$151K | ﹤0.01% | 3326 |
|
|
2022
Q2 | $682K | Buy |
164,738
+58,368
| +55% | +$206K | ﹤0.01% | 3587 |
|
|
2022
Q1 | $404K | Buy |
106,370
+884
| +0.8% | +$3.98K | ﹤0.01% | 4054 |
|
|
2021
Q4 | $474K | Buy |
105,486
+6,683
| +7% | +$33.9K | ﹤0.01% | 4078 |
|
|
2021
Q3 | $460K | Buy |
98,803
+25,403
| +35% | +$135K | ﹤0.01% | 4068 |
|
|
2021
Q2 | $517K | Sell |
73,400
-46,157
| -39% | -$249K | ﹤0.01% | 3925 |
|
|
2021
Q1 | $706K | Buy |
119,557
+19,202
| +19% | +$116K | ﹤0.01% | 3693 |
|
|
2020
Q4 | $462K | Sell |
100,355
-13,973
| -12% | -$60.2K | ﹤0.01% | 3616 |
|
|
2020
Q3 | $444K | Sell |
114,328
-1,374
| -1% | -$27.6K | ﹤0.01% | 3460 |
|
|
2020
Q2 | $3.33M | Buy |
115,702
+33,810
| +41% | +$783K | ﹤0.01% | 2552 |
|
|
2020
Q1 | $1.76M | Buy |
81,892
+17,389
| +27% | +$395K | ﹤0.01% | 2736 |
|
|
2019
Q4 | $1.27M | Buy |
+64,503
| New | +$917K | ﹤0.01% | 3186 |
|
Geode Capital Management's STSA Position: Q2 2023 in Review
Geode Capital Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 414,344 shares — an estimated $289K sold.
Geode Capital Management first reported a position in STSA in Q4 2019 and held it in 14 quarters. The position peaked at $3.33M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Geode Capital Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Geode Capital Management sold 414,344 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $289K.
- Geode Capital Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Geode Capital Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $3.33M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.